127 studies found for:
thalidomide myeloma | Open Studies
| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 1 | Recruiting |
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
|
||||
| 2 | Recruiting |
Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
|
||||
| 3 | Unknown † |
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
|
||||
| 4 | Recruiting |
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
|
||||
| 5 | Recruiting |
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
|
||||
| 6 | Unknown † |
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
|
||||
| 7 | Recruiting |
Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
|
||||
| 8 | Recruiting |
Escalating Doses Thalidomide+Bortezomib+HIgh Dose Melphalan for Auto PBSC Transplant in Patients With Multiple Myeloma
|
||||
| 9 | Unknown † |
Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
|
||||
| 10 | Recruiting |
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
|
||||
| 11 | Unknown † |
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
|
||||
| 12 | Recruiting |
Velcade (Bortezomib) Consolidation After Transplant
|
||||
| 13 | Recruiting |
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
|
||||
| 14 | Recruiting |
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
|
||||
| 15 | Recruiting |
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
|
||||
| 16 | Recruiting |
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
|
||||
| 17 | Unknown † |
TCD Followed by autoSCT for Newly Diagnosed MM Patients
|
||||
| 18 | Unknown † |
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
|
||||
| 19 | Recruiting |
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
|
||||
| 20 | Unknown † |
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
|
† Indicates status has not been verified in more than two years
